Gynecologic Cancers
Questions discussed in this category
E.g. a patient with progression of their primary cancer but still is testing COVID19+ over a month after infection?
I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6000
Does residual grade 1-2 neuropathy from Taxol/ carbo 10 years ago affect your recommendation?
Would you have reservations in treating patients with breast, GI, or pelvic malignancies with radiation alone or concurrent chemoradiation?
http://abstracts.asco.org/199/AbstView_199_180760.html
http://abstracts.asco.org/199/AbstView_199_187537.html
Does cisplatin need to be administered on the start date of radiation
What if the sentinel nodes demonstrate macrometastatic disease?
If the patient had high risk features (for example age 60+ and LVI) do you treat with vaginal brachytherapy or WPRT? If you treat with whole pelvis ra...
Do you treat the whole bladder in the intial whole pelvic field to 45-50 Gy?
If an external boost of a gyn primary is necessitated because of the target size or extensive involvement of a critical structure how would ...
How would tumor grade, presence of LVSI, and receipt of chemotherapy factor into your decision?
Given recent approval of niraparib (Zejula) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or prima...
This is not the standard of care in the USA.
This has been a common practice in the community. Is there a benefit for certain patients?
Does the GOG 249 abstract guide you one way or the other?
How do you counsel a pre-menopausal female with endometrioid cancer desiring definitive RT with egg harvesting and IVF for fertility preservation inst...
Sentinel Lymph Nodes negative
What dose/fractionation would you recommend?
How would you approach a patient who is receiving chemoRT but has confirmed COVID-19 with minor symptoms, as breaking treatment for 2 weeks quarantine...
Small bowel is usually the dose limiting OAR while planning cervical HDR brachytherapy. Having the bladder empty during treatment planning and deliver...
When a physical exam is important and telehealth is not a good option, should we be proactive and reschedule or should we continue to see them as sche...
No adjuvant treatment was given upfront
How do you prevent early menopause in women? Please comment on freezing of eggs, oophopexy, supine vs prone position, vaginal dialator.
Margins are negative.
Specifically, if they are to be treated similar to GI cancers that receive FOLFOX/EPIC
MRI with intravaginal gel shows no gross residual disease.
Insurance authorization for protons is pending, but if the patient cannot have protons would you treat with standard fractionation to ~70Gy or conside...
NCCN recommends brachytherapy plus or minus pelvic RT for surgically staged Grade 1, Stage II patients, but these originally staged IIB patients were ...
What fields would you cover and how much dose would you boost to the primary?
Since there is no overall survival benefit, does the local control benefit outweigh the increased risk for distant metastasis? How do you select patie...
Would you consider EBRT or brachytherapy boost to the nodes? what dose would you recommend?
What field and dose would you recommend? Would you consider whole abdominal?
For the management of stage II endometrial cancer, NCCN says pelvic RT and/or vaginal brachytherapy. Do you ever add vaginal cuff boost to pelv...
If so, would you treat the whole pelvis, cuff brachytherapy, or both?
The patient had an initial partial vulvectomy and nodal dissection 6 years prior to recurrence, with no adjuvant RT offered initially due to lack of c...
Patient being treated for cervical cancer noted to have a < 1 cm posterior vaginal fornix defect with a small focus epiploclia herniating into the ...
SOLO1 trial studied stage 3/4 patients.
Would you recommend any planning techniques or dosimetric constraints in this scenario?
The limited data on MDA (minimum deviation adenocarcinoma) suggests it has a worse prognosis, but it is hard to disentangle this from stage, as it is ...
MRI and cervical biopsy are negative for cervical involvement
Would there be a substanital increase in the risk of toxicity using such a scheme?
We frequently have patients who have to travel long distance...
In December 2018, Horn et al reported the results of a phase 3 clinical trial in the NEJM (N Engl J Med 2018; 379:2220-2229). This trial included prev...
The initial treatment did not include any adjuvant chemotherapy or radiation therapy.
How long after hysterectomy would you consider delivering adjuvant radiation therapy? Would this differ for external beam versus brachytherapy?
Are t...
Would you be more or less likely to use a cisplatin-containing regimen if a patient had previously responded to chemoradiation with concurrent cisplat...
For a patient with vaginal adhesions/stenosis, do you recommend any other therapy besides a dilator?
Would estrogen cream be helpful in this scenario?
If so, are there any lymph node cut-offs you would have in terms of lymph node number or pathological ECE before you would add contralateral RT? What ...
Could you discuss how you decide between IMRT or SBRT boost for a patient who is not able to receive intracavitary or interstitial HDR or LDR brachyth...
https://www.nejm.org/doi/full/10.1056/NEJMoa1813181
are there any positive or negative synergies from combined megestrol/RT treatment?
Should these patients be managed similar to p16 positive anal squamous cell carcinoma, and allowed six months or more for complete regression before c...
What chemotherapy and sequencing with radiation therapy would you recommend? IS surgery a component of the treatment?
Is pembrolizumab considered standard of care in the 2nd line treatment of recurrent cervical cancer?
Does the phase II KN-158 provide sufficient evidence to change management?
Should this be done at the time of recurrence or after failure of 1st line therapy for recurrence?
With the recent publication of GOG252 - does this change your management for patients with ovarian cancer who undergo primary surgery who have an opti...
What is your typical treatment depth prescribed to? What length of vaginal mucosa do you typically treat?
Do you have an SUV cutoff for physiologic activity of the ovary?
How does fertility preservation factor into your decision making?
Surgeon is not planning vulvectomy, since biopsies showed 2 mm depth of invasion.
Also tumor board felt dose to the primary site should be only about...
In a patient, with multiple small volume lesions (5-25mm), would you offer pelvic RT?
At what point would you introduce the discussion of weight management, whether for risk reduction or overall health?
Do you cover common iliac nodes (L3/L4) or keep field edge at L4/L5 to reduce bone marrow toxicity?
The NCCN recommends either systemic therapy + brachytherapy or pelvic RT + brachy or brachy alone or observation. How do you decide among these option...
The disease involving the endocervix was felt to be separate and appeared like a drop metastases
Specifically, is hyperbaric oxygen therapy (HBO) an effective treatment for refractory radiation cystitis?
Given the recent press release regarding the update on the phase 3 soft tissue sarcoma study of LARTRUVO (olaratumab) showing no benefit to the combin...
If so, what indications would you use other than Peters criteria?
What would be factors that would indicate the need to include the pelvic nodes?
Do you use a trimmed 10 mm expansion on HR-CTV? Do you also include the entire initial extent of disease? How much does your IR-CTV coverage affect yo...
Should this be the new standard of care based on the results from the recently published SOLO-1 trial?
Two new phase 2 studies this year with apatinib/oral etoposide (AEROC) and sorafenib/topotecan (TRIAS) were released, and NCCN also lists many single ...
What dose would you use?
Female in her 60s who had presented originally with well-differentiated endometrioid adeno clinically and radiographically involving bilateral paramet...
For a woman with complete resection of serous intraepithelial carcinoma of the endometrium, would you recommend adjuvant radiation or chemotherapy? Wh...
Current NCCN guidelines suggest that vaginal brachytherapy is optional, and there may be concern for over-treatment locally given competing risk of di...
A literature search indicates that most port site recurrences are managed fairly aggressively with chemoRT or RT doses 45-66 Gy. This is understandabl...
Or do you wait for platinum resistance?
Sequentially or do you integrate the cuff brachy with the EBRT and if so what schedule, BIW, weekly, etc?
Hydrogen peroxide douches? Antibiotics? (If so, what are you covering?) When do you initiate hyperbaric oxygen? Do you find pentoxyfyline helpful? How...
When you prescribe your dose at 0.5 cm depth of the vagina? For instance, if you measure a vaginal length to be 8 cm, would you prescribe to treat 4 c...
Would organ invasion (bladder/rectum), size, feasibility of T&O, or size of nodes push you toward neoadjuvant chemotherapy?
While EBRT + brachy may be preferred, what treatment would you offer if surgery has been performed? What dose and volume of EBRT, brachytherapy, or bo...
How do you weigh this concern with the need to prophylactically treat non-involved, high risk para-aortic lymphatics?
How high would you extend your field? Would you treat differently if the patient had lower PET avid pelvic lymph nodes?
Do you use size criteria (i.e. bulky nodes over 3 cm), specific adverse histology (adenocarcinoma), or location (near small bowel), etc.
Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however ...
More recent Italian (Sozzi et al) and French data (Canlorbe et al) show associations of greater tumor size > 25-35mm with higher rates of local &am...
She has extensive colposcopic lesions at upper/mid vagina, but no palpable/visible lesions on standard pelvic exam. Pelvic MRI with 20cc US gel in vag...
PORTEC-3 assigned women with high risk stage I or stage II-III endometrial carcinoma to adjuvant external beam radiation vs adjuvant chemoradiation wi...
Is it reasonable to use single agent carboplatin for elderly patients?
Has your institution changed practice patters based on the findings of the LACC Trial (Pedro et al., SGO in 3/2018) showing worse outcomes with roboti...
Would you deliver definitive RT in place of inguinal lymph node dissection in light of new data (PMID: 29336837)
In the case of high risk but radiogr...
NCCN guidelines mention EBRT/vaginal brachytherapy as options in addition to chemotherapy in the adjuvant setting for high grade histologies, stages 1...
Apart from H&N SCC, are there times where adding an extra dose of radiation due to a tx break is appropriate? Is there a decent equatio...
If the patient is responding to external beam and likely to be converted to resectable, what brachytherapy dose/fractionation do you prescribe and wha...
Assuming no distant metastases, should this scenario be managed with "sequential" chemoradiation to the para-aortic region with an external beam boost...
For HDR brachytherapy for cervical cancer do you use the dose optimization algorithm? Is there a standard dwell time distribution that should be...
For example, assuming an excellent performance status, would you consider local radiation to the primary and metastasis in someone with a single ...
Patient had a single 3cm node s/p excisional biopsy of the one node without nodal dissection. We have done anoscopy and a thorough GYN exam...
EBRT boost only? SBRT? If you recommend interstitial brachytherapy do you place needles freehand or with a template based approach?
What have your liked or disliked about these newer applicators?
In a patient who underwent laparoscopy for endometriosis and was found to have a 1mm focus of neuroendocrine tumor, would you recommend further surger...
if so, would you favor brachytherapy alone? What dose?
What would be the appropriate treatment for grade I endometrial cancer s/p TAH/BSO but with SLNB yielding negative nodes. The uterus contained a 2cm t...
Assuming the early stage endometrial cancer was treated with TAH+BSO initially and no further treatment, what would your recommendations be for HGIL? ...
If so what dose/fractionation? This was reported here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918530/
For women treated with IMRT, there are multiple ways to define the upper border of the field
1) contouring the PAs up to where the renal vessels exit...
She has metastatic disease beyond the pelvis (lungs).
Type II endometrial cancers made up roughly 15% of GOG 249 the study population, but seemed to be balanced between both arms.
Single institutio...
After whole pelvis radiation therapy, what would be the highest dose you would allow in a single fraction, versus the total course EQD2 for small bowe...
Would you consider this in a patient with a single omental metastasis found and no other distant spread after surgery?
For example, a patient with cervical or anal SCC who has missed many treatments due to side effects, low blood counts, hospitalizations, or non-compli...
What factors influence your decision? Does high grade histology or pathological stage play a role? If the patient received chemotherapy due to +LN, pa...
Do you recommend upfront diversion? Are there unique planning considerations such as the inability to use bladder filling? How do you boost? What are ...
Do you add an IMRT boost with possibly vaginal brachytherapy?
What are your specific protocols for monitoring and for dosing narcotics and sedatives?
If so, what dose/ volume is prescribed? How do you account for motion?
What dose and technique do you use and how do you integrate the subsequent definitive treatment plan?
In what situations is it appropriate to offer observation (rather than VBT) to patients with stage II endometrial carcinoma who have had a radical hys...
If a patient has a gynecological cancer, how long should one wait after RT before a screening colonoscopy can be completed?
Would you approach this situation as synchronous primaries (eg. FIGO IA in both) or as a locally advanced endometrial cancer (FIGO IIIA)?
What adjuva...
Does definitive or adjuvant setting effect your planned dose? For example, for a woman with IB2 cervical cancer status post hysterectomy, who wa...
When should pelvic/inguinal lymph nodes be included?
VC brachy, pelvic RT, +/- chemo?
Does your management change if it is confined to the endometrium without myometrium invasion or if it is only ...
Do you assume some recovery since the prior course of RT? If so, how much over what time period?
Would you utilize IMRT to provide a boost to gross disease? If so, how would you define your treatment volumes and what dose would try to achieve? Als...
Would you still consider this high risk? If so, would you recommend pelvic radiation AND chemotherapy?
Would you add chemotherapy if there was gross residual disease, pN+ and/or ECE?
Can the classic indications for post-hysterectomy radiation (eg. "Sedlis" and "Peter's" criteria) be applied? Does the histology change radiation dose...
Is there evidence for SBRT for recurrent ovarian granulosa cell tumors?
If offering radiation therapy, would you treat extended field whole pelvis or just cover the para-aortic LNs with an involved field volume? Would your...
How many cycles do you prefer before and after? How long do you tend to wait before starting radiation after initial chemo and after radiation to resu...
What are the pros and cons of completing a simple hysterectomy versus aborting surgery followed by chemoRT?
With stage I/II vaginal cancer and an excellent response to 4500cGy EBRT with <5mm residual thickness of tumor remaining, what is your dose/fractio...
When do you continue with treatment and when do you terminate the plan? What is your criteria?
Close but negative radial margins? LVSI? What fractionation/dose do you use for your vaginal cuff boost if used?
Would your recommendations change based on stage? What factors would influence your decision to include presacral lymph nodes in a locally advanced en...
Does this differ if the primary is vaginal? Do you prescribe the same dose when using an intracavitary applicator for cervix cancer?
For palliation of vulvar cancer, what fractionation due you typically use. Can some of the toxicity be avoided with a shorter course of treatmen...
For instance, if you have anal canal involvement, do you cover the entire mesorectum? Any other adjacent organ invasion that would lead to modif...
Prior to starting vaginal cuff brachytherapy, do you wait for a specificed period of time prior to vaginal cuff brachy after hysterectomy? Do y...
With the results of the EMBRACE protocol, how do you approach MRI planning? Do you plan with applicators in situ, or use preimplant (post EBRT) ...
Does this management depend on treatment site?
For definitive vulvar ca, is 5940 cGy the minimum acceptable dose for gross disease? 5760cGy? Or should the dose be escalated beyond 60Gy?
Does time since adjuvant cuff brachytherapy influence your radiotherapy approach, (for example 18 months vs 5 years)? Do you adjust your bladder/bowel...
Can the drug continue during radiation therapy or should it be discontinued at a specified time prior to initiation of radiation?
And if so, in which situations do you offer differing doses?
For example, would you consider adjuvant chemotherapy alone to be sufficient in a patient with an isolated pelvic recurrence and positive margin after...
For example, how do you decide between applicators such as tandem and ovoid versus tandem split ring insertion for cervical brachytherapy patients?&nb...
For instance, RTOG 0418 did not allow clear cell or papillary serous histologies, but subsequent trials that allow IMRT have (GOG 0249, 0258, RTOG 120...
Interstitial needles can result in hot spots in the bladder, but how well tolerated is that? On the other hand, intracavitary applicators usually don'...
For example, in an otherwise intermediate risk localized endometrial cancer (Grade 2, FIGO IB)?
What clinicopathologic features do you typically consider?
In the setting of a negative lymph node sampling, would you treat a full pelvis or mini-pelvis to compensate for lack of the appropriate surgery? Is a...
In patients who don't meet traditional criteria for adjuvant chemoradiation from Peters (GOG 109) and < 2 high risk factors from Rotman (GOG 92) fo...
If the post-operative simulation films reveal a significant lymphocele secondary to pelvic lymph node sampling, is it imperative that the entire lymph...
The gyn oncs at my institution sometimes will not perform lymphadenectomy if biopsy indicates low risk disease. Would LVSI as sole adverse risk factor...
Do you use SIB or sequential approach? Do size of lymph nodes influence your dose or decision?
Do you give cuff and chemo or pelvic CRT or chemo alone?
Is there any indication for ENI in early stage disease or in advanced stages, without pathologic confirmation or PET positivity or CT size criteria?
What exactly do you contour and what is your dose constraint to that volume?
Does using something like a vienna applicator allow you to avoid dose escalation with more external beam? How do you recommend doing a classic pa...
Some classic references recommend the coverage of the entirety of the sacrum but the volume delineation guidelines for both seem to only cover the mos...
Do you try to keep Hb> 10 or 12? Or somewhere in between?
The patient failed previous excisions and medical therapy and is no longer a surgical candidate.
Does hydroureter and leg edema alter your opinion?
Brachytherapy, EBRT or both and what is the best dose?
How should we counsel young women who are receiving treatment for GI/GYN malignancies?
Do you plan every fraction, every other fraction, or use one plan for the whole treatment?
The most recent ABS guidelines don't discuss a dose constraint for the small bowel.
What schedule is best for preventing fibrosis and for patient compliance?
Does your strategy change if bladder invasion is present?
Do you treat PAs if pelvic nodes are positive? If common iliacs are involved? Only if there are positive PA nodes?
Do the urethral constraints used in prostate brachytherapy apply to women undergoing gyn brachy?
Papers discussed in this category
Gynecologic oncology, 2004-03
Int. J. Radiat. Oncol. Biol. Phys., 2011-11-15
Lancet, 2010-03-06
Obstet Gynecol, 1980-10-01
Lancet (London, England), 2009-01-10
Int. J. Radiat. Oncol. Biol. Phys., 2005-08-01
Int. J. Radiat. Oncol. Biol. Phys., 1990-02-01
Brachytherapy, 2013
International journal of radiation oncology, biology, physics, 2011-02-01
Int J Radiat Oncol Biol Phys, 2013 Jul 9
Gynecologic oncology, 2003-12
Int. J. Radiat. Oncol. Biol. Phys., 2014-05-01
Brachytherapy, 2015
Gynecologic oncology, 2014-11
International journal of radiation oncology, biology, physics, 2018-08-01
Brachytherapy, 2019 Sep - Oct
Gynecologic oncology, 2009-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-01-01
Gynecologic oncology, 2013-10
Gynecologic oncology, 2013-01
Eur. J. Cancer, 2010 Jul 07
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-07-20
American journal of clinical oncology, 2015-06
Curr Urol Rep, 2018 Apr 13
Urology, 2016 Apr 25
Urology, 2005-04
The Journal of urology, 1999-02
Urol. Int., 2012 Jul 10
Gynecologic oncology, 2014-12
Gynecologic oncology, 2013-08
J Clin Oncol, 2012 May 10
Ann. Oncol., 2011-02-01
Gynecologic oncology, 2010-03
Int. J. Radiat. Oncol. Biol. Phys., 2012 Aug 14
International journal of radiation oncology, biology, physics, 1994-07-30
Obstet Gynecol, 2009-09-01
Radiother Oncol, 2015 24
Brachytherapy, 2012
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011-07
The Lancet. Oncology, 2017-03
Gynecol. Oncol., 2008-11-01
Eur. J. Cancer, 2016-09-01
Gynecologic oncology, 2017-11
Brachytherapy, 2019 Apr 17
The New England journal of medicine, 2019-06-13
Lancet Oncol., 2019 Jul 22
Gynecologic oncology, 2004-04
American journal of obstetrics and gynecology, 2010-10
Obstetrics and gynecology, 1988-01
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014-11
Gynecologic oncology, 2015-06
International journal of radiation oncology, biology, physics, 2017-03-01
Gynecologic oncology, 2006-10
Gynecologic oncology, 2009-03
Br. J. Cancer, 2006-08-07
Gynecol. Oncol., 2009-07-01
Medicine (Baltimore), 2015-04-01
The Lancet. Oncology, 2017-09
Cancer Nurs, 2017-04-21
American journal of clinical oncology, 2018-08
Gynecologic oncology, 2014-12
International journal of radiation oncology, biology, physics, 2005-12-01
Cancer, 1987-10-15
Gynecologic oncology, 2015-09
Brachytherapy, 2016 Nov - Dec
Radiother Oncol, 2016-09-01
International journal of radiation oncology, biology, physics, 2013-04-01
International journal of radiation oncology, biology, physics, 2013-09-01
Eur. J. Obstet. Gynecol. Reprod. Biol., 2015 Aug 22
Cancer Res Treat, 2014 Jan 15
Gynecologic oncology, 2017-11
Curr Oncol Rep,
Adv Anat Pathol,
International journal of radiation oncology, biology, physics, 2005-05-01
International journal of radiation oncology, biology, physics, 1992
Radiother Oncol, 2016 Apr 29
Gynecologic oncology, 2014-05
N Engl J Med, 2016 Feb 25
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-01
The New England journal of medicine, 2011-12-29
N Engl J Med, 2011 Dec 29
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-09-10
International journal of radiation oncology, biology, physics, 2014-12-01
Practical radiation oncology, 2015
Curr Oncol Rep,
Cochrane Database Syst Rev,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-06-10
Lancet Oncol, 2017 Jun
Lancet (London, England), 2017-10-28
The New England journal of medicine, 2016-12-01
The New England journal of medicine, 2012-04-12
J. Clin. Oncol.,
J Clin Oncol, 2014 May 1
Int J Gynecol Cancer, 2018 Mar
Br. J. Cancer,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015-02
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014-10
Cochrane Database Syst Rev, 2010 Sep 08
Practical radiation oncology, 2017
Gynecologic oncology, 2018-08
The New England journal of medicine, 2018-12-27
International journal of radiation oncology, biology, physics, 2017-04-01
International journal of radiation oncology, biology, physics, 2019-05-01
Cochrane Database Syst Rev, 2012 May 16
Int. J. Gynecol. Cancer,
Gynecologic oncology, 2018-10
Int J Clin Exp Med, 2015 Sep 15
Pathol. Int.,
Oncotarget,
Semin Radiat Oncol, 2004-01-01
Practical radiation oncology, 2017
Seminars in radiation oncology, 2019-04
International journal of radiation oncology, biology, physics, 1994-06-15
International journal of radiation oncology, biology, physics, 2010-12-01
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010-06
International journal of radiation oncology, biology, physics, 2006-08-01
Gynecologic oncology, 2005-11
Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-12-15
Science (New York, N.Y.), 2017-07-28
The New England journal of medicine, 2018-05-31
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-12-20
Gynecol Oncol, 2017 Aug
J Gynecol Oncol, 2015 Nov 23
Int J Gynaecol Obstet,
Int J Womens Health, 2017 May 02
Lancet Oncol, 2013 Sep
J. Clin. Oncol., 2019 Apr 19
Radiat Oncol, 2015 Feb 22
Obstet Gynecol,
Annals of surgical oncology, 2016-05
Gynecologic oncology, 2018-12
Br. J. Cancer, 2009 Feb 17
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011-05
The New England journal of medicine, 2006-01-05
Gynecologic oncology, 2019-06
Obstet Gynecol,
Obstetrics and gynecology, 2013-09
Lancet Oncol.,
Gynecol. Oncol., 2005 Dec 20
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01
Gynecol. Oncol., 2017 Jul 30
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-04
Lancet,
Gynecol. Oncol., 2005 Nov 21
Lancet Oncol., 2020 Feb 14
Ann. Oncol., 2020 Mar 26
International journal of radiation oncology, biology, physics, 2014-03-15
Gynecol. Oncol., 2015 Sep 30
Current treatment options in oncology, 2018-11-15
Gynecol. Oncol., 2019 Oct 17
J Oncol Pharm Pract, 2020 Jan 06
Gynecol. Oncol.,
Lancet, 2019 Nov 29
Lancet Oncol., 2014 Feb 28
Lancet,
Brachytherapy, 2015
J Clin Oncol, 2020 Feb 10
N Engl J Med, 2019 Dec 19
N. Engl. J. Med., 2019 Sep 28
Gynecologic oncology, 2009-08
Lancet Oncol.,
Br. J. Cancer, 2018 Oct 24
J. Clin. Oncol., 2011 Mar 28
BMC Cancer, 2017 Apr 28
Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-02-15
Int. J. Radiat. Oncol. Biol. Phys., 2015 Jan 30
Lancet Oncol., 2018 Feb 12
Gynecol. Oncol., 2018 Aug 03
European journal of cancer (Oxford, England : 1990), 2012-07
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-09-15
Clin Transl Radiat Oncol, 2018 Jan 11
N. Engl. J. Med.,
Nature, 2013-05-02
Gynecologic oncology, 2019-09
F1000Res, 2019 Jun 12
AJNR. American journal of neuroradiology, 1996-02